pelareorep
AXP000004.1 · Oncolytic virus
- Platform
- reovirus (serotype 3 Dearing, unmodified)
- Originator
- Oncolytics Biotech
- Sponsor
- Oncolytics Biotech
Names
| Name | Type | Source |
|---|---|---|
| pelareorep | preferred name, INN | curator, ncit |
| Reolysin | brand | ncit |
| PO-BB0209 | code | ncit |
| Reovirus Serotype 3 ambiguous | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Spinareoviridae
- Virus
- mammalian orthoreovirus (NCBI Taxonomy 351073)
- Strain
- type 3 Dearing
- Replication
- replicating
- Modifications
- none (wild-type isolate)
- Route
- intravenous, intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C60774
- Wikidata
- Q7313867
- FDA UNII
- S9J80L3D1U
Approvals
No regulatory approval recorded.
Clinical trials (35)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07446322 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | Recruiting | Phase 2 | 2026-04-30 | 2027-08-30 | 60 | MSS Metastatic Colorectal Cancer; Ras-mutated Metastatic Colorectal Cancer; mCRC |
| NCT05514990 | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | Active not recruiting | Phase 1/2 | 2022-10-07 | 2026-12-31 | 10 | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | Active not recruiting | Phase 1/2 | 2021-10-27 | 2027-07-30 | 122 | Anal Cancer Metastatic; Pancreatic Cancer Metastatic; Squamous Cell Carcinoma of the Anus Stage Unspecified; Unresectable Pancreatic Carcinoma |
| NCT05519059 | Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | Completed | Phase 1 | 2021-10-11 | 2022-09-29 | 15 | Advanced or Metastatic Breast Cancer |
| NCT04445844 | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | Active not recruiting | Phase 2 | 2020-07-13 | 2025-06-30 | 25 | Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Triple-negative Breast Cancer |
| NCT04215146 | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | Active not recruiting | Phase 2 | 2020-06-10 | 2022-08-01 | 48 | Breast Cancer Metastatic |
| NCT04102618 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | Terminated | Early phase 1 | 2019-03-29 | 2022-04-20 | 26 | Breast Cancer |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | Terminated | Phase 2 | 2018-11-14 | 2019-12-19 | 17 | Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
| NCT03605719 | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma | Completed | Phase 1 | 2018-10-24 | 2022-10-10 | 23 | Recurrent Plasma Cell Myeloma |
| NCT03282188 | REO13 Melanoma With of Without GM-CSF | Withdrawn | Phase 1/2 | 2017-10 | 2018-07 | 0 | Cancer of Skin; Melanoma |
| NCT03015922 | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma | Unknown | Phase 1 | 2017-06-05 | 2021-09-01 | 4 | Multiple Myeloma |
| NCT02723838 | Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder | Withdrawn | Phase 1 | 2017-02-28 | 2017-09-30 | 0 | Muscle-invasive Transitional Cell Carcinoma of the Bladder |
| NCT02620423 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | Completed | Phase 1 | 2015-12 | 2018-03 | 11 | Pancreatic Adenocarcinoma |
| NCT02514382 | Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | Phase 1 | 2015-08-21 | 2022-04-19 | 14 | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
| NCT02444546 | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | Completed | Phase 1 | 2015-06-21 | 2018-07-13 | 6 | Childhood Astrocytoma; Childhood Atypical Teratoid/Rhabdoid Tumor; Diffuse Intrinsic Pontine Glioma; Glioma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Brain Neoplasm; Recurrent Childhood Glioblastoma; Recurrent Childhood Medulloblastoma; Recurrent Primitive Neuroectodermal Tumor; Refractory Brain Neoplasm |
| NCT02101944 | Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | Phase 1 | 2014-12-09 | 2021-05-05 | 12 | Anemia; Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
| NCT01656538 | A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | Completed | Phase 2 | 2013-02-20 | 2016-11-18 | 81 | Metastatic Breast Cancer |
| NCT01619813 | Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | Completed | Phase 2 | 2012-12-14 | 2016-04-26 | 85 | Prostate Cancer |
| NCT01708993 | Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy | Completed | Phase 2 | 2012-12-10 | 2016-01-26 | 166 | Non Small Cell Lung Cancer |
| NCT01622543 | Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer | Completed | Phase 2 | 2012-10-26 | 2017-01-18 | 109 | Colorectal Cancer |
| NCT01533194 | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | Phase 1 | 2012-04 | 2015-02 | 12 | Light Chain Deposition Disease; Refractory Plasma Cell Myeloma |
| NCT01199263 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Completed | Phase 2 | 2010-12-06 | 2015-06-01 | 108 | Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | Completed | Phase 2 | 2010-12 | 2016-01-19 | 73 | Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer |
| NCT01274624 | Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | Completed | Phase 1 | 2010-12 | 2018-02 | 36 | KRAS Mutant Metastatic Colorectal Cancer |
| NCT01240538 | Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors | Completed | Phase 1 | 2010-12 | 2014-04 | 26 | Unspecified Childhood Solid Tumor, Protocol Specific |
| NCT01166542 | Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers | Completed | Phase 3 | 2010-06 | 2012-04 | 167 | Carcinoma, Squamous Cell of the Head and Neck |
| NCT00998322 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | Completed | Phase 2 | 2009-10 | 2013-12 | 34 | Metastatic Pancreatic Adenocarcinoma |
| NCT00998192 | A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung | Completed | Phase 2 | 2009-10 | 2013-09 | 32 | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung |
| NCT00984464 | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | Completed | Phase 2 | 2009-09 | 2014-02 | 14 | Metastatic Melanoma |
| NCT00861627 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | Completed | Phase 2 | 2009-03 | 2015-09 | 37 | Carcinoma, Non-small Cell Lung |
| NCT00753038 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma | Completed | Phase 2 | 2008-08 | 2011-07 | 14 | Carcinoma, Squamous Cell of the Head and Neck |
| NCT00651157 | Viral Therapy in Treating Patients With Metastatic Melanoma | Completed | Phase 2 | 2008-04 | 2011-12 | 23 | Recurrent Melanoma; Stage IV Melanoma |
| NCT00602277 | Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy | Completed | Phase 1 | 2008-04 | 2016-08 | 70 | Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
| NCT00503295 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung | Completed | Phase 2 | 2007-06 | 2011-02 | 53 | Ewing Sarcoma Family Tumors; Fibrosarcoma; Leiomyosarcoma; Malignant Fibrous Histiocytoma; Osteosarcoma; Sarcoma, Synovial |
| NCT00528684 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas | Completed | Phase 1 | 2006-07 | 2010-04 | 18 | Malignant Glioma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39828738 | Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects. | Journal of hematology & oncology | 2025 | cited by trial NCT02101944 |
| PMID 40300087 | A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in title: pelareorep |
| PMID 37443348 | Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). | British journal of cancer | 2023 | cited by trial NCT03723915 |
| PMID 37812476 | Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | cited by trial NCT02514382 |
| PMID 33168658 | Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2021 | name in title: pelareorep |
| PMID 31694832 | Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2020 | name in title: pelareorep |
| PMID 32156785 | Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. | Molecular cancer therapeutics | 2020 | name in title: pelareorep |
| PMID 29027598 | A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. | Breast cancer research and treatment | 2018 | cited by trial NCT01656538 |
| PMID 29186319 | OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. | Annals of oncology : official journal of the European Society for Medical Oncology | 2018 | cited by trial NCT01622543 |
| PMID 29487723 | A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. | Oncotarget | 2018 | cited by trial NCT01619813 |
| PMID 29653857 | A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. | Clinical colorectal cancer | 2018 | cited by trial NCT01622543 |
| PMID 29748010 | Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. | Lung cancer (Amsterdam, Netherlands) | 2018 | cited by trial NCT01708993 |
| PMID 28289863 | A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. | Cancer chemotherapy and pharmacology | 2017 | name in title: pelareorep |
| PMID 28756871 | Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. | Gynecologic oncology | 2017 | name in title: Reolysin |
| PMID 26719427 | Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2016 | cited by trial NCT01280058 |
| PMID 27039845 | Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. | Molecular therapy : the journal of the American Society of Gene Therapy | 2016 | cited by trial NCT01280058 |
| PMID 25728527 | A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. | Pediatric blood & cancer | 2015 | name in title: Reolysin |
| PMID 26156229 | The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. | BMC cancer | 2015 | name in title: Reolysin |
| PMID 25294913 | A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2014 | name in title: Reolysin |
| PMID 26184025 | Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature. | Clinical journal of gastroenterology | 2014 | name in abstract: Reolysin |
| PMID 22886613 | REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. | Investigational new drugs | 2013 | name in title: Reolysin |
| PMID 22871663 | Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. | Molecular therapy : the journal of the American Society of Gene Therapy | 2012 | name in title: Reolysin |
| PMID 23121273 | Clinical trials involving the oncolytic virus, reovirus: ready for prime time? | Expert review of clinical pharmacology | 2012 | name in abstract: Reolysin |
| PMID 19572105 | Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. | Investigational new drugs | 2010 | name in title: Reolysin |
| PMID 20926400 | REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2010 | name in abstract: Reolysin |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41741902 | Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. | Journal of neuro-oncology | 2026 | name in abstract: Reolysin |
| PMID 41963749 | In Vivo Tracking Modalities for Oncolytic Reovirus: Principles, Clinical Applications, and Translational Integration. | Molecular imaging and biology | 2026 | name in abstract: pelareorep |
| PMID 42105076 | Identification of reovirus reassortants with enhanced oncolytic activity in human fibrosarcoma cells. | Virus genes | 2026 | name in abstract: pelareorep |
| PMID 42248646 | Operation oncolysis: Reoviruses in the theater of cancer war. | Advances in cancer research | 2026 | name in abstract: pelareorep |
| PMID 42456895 | Oncolytic viruses in cancer therapy: Mechanisms, challenges, and emerging clinical applications. | Annales pharmaceutiques francaises | 2026 | name in abstract: pelareorep |
| PMID 41228258 | The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management. | Cancers | 2025 | name in abstract: pelareorep |
| PMID 41463198 | Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions. | Cancers | 2025 | name in abstract: pelareorep |
| PMID 38194598 | Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies. | Cancer immunology research | 2024 | name in abstract: pelareorep |
| PMID 36154608 | Gene Therapy Cargoes Based on Viral Vector Delivery. | Current gene therapy | 2023 | name in abstract: Reolysin |
| PMID 36744961 | p38 Mitogen-Activated Protein Kinase Signaling Enhances Reovirus Replication by Facilitating Efficient Virus Entry, Capsid Uncoating, and Postuncoating Steps. | Journal of virology | 2023 | name in abstract: pelareorep |
| PMID 36992407 | Viral Vectors in Gene Therapy: Where Do We Stand in 2023? | Viruses | 2023 | name in abstract: Reolysin |
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: pelareorep |
| PMID 37829303 | Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis. | Frontiers in pharmacology | 2023 | name in title: pelareorep |
| PMID 34004331 | Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. | Seminars in cancer biology | 2022 | name in abstract: pelareorep |
| PMID 35487285 | Clinical advances in oncolytic virotherapy for pediatric brain tumors. | Pharmacology & therapeutics | 2022 | name in abstract: pelareorep |
| PMID 35796248 | GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers. | Future oncology (London, England) | 2022 | name in title: pelareorep |
| PMID 35821679 | Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. | Neuro-oncology advances | 2022 | name in title: pelareorep |
| PMID 35836877 | Advances in the clinical development of oncolytic viruses. | American journal of translational research | 2022 | name in abstract: pelareorep |
| PMID 33924556 | Oncolytic Virotherapy for Cancer: Clinical Experience. | Biomedicines | 2021 | name in abstract: Reolysin |
| PMID 34332591 | Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis. | Virology journal | 2021 | name in abstract: pelareorep |
| PMID 34372612 | Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma. | Viruses | 2021 | name in abstract: pelareorep |
| PMID 35035763 | Multimodal immune activation abilities and characteristics of reovirus. | American journal of translational research | 2021 | name in abstract: pelareorep |
| PMID 35116288 | The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis. | Translational cancer research | 2021 | name in abstract: Reolysin |
| PMID 33108458 | Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy. | Blood advances | 2020 | name in abstract: Reolysin |
| PMID 33142841 | Past, Present and Future of Oncolytic Reovirus. | Cancers | 2020 | name in abstract: pelareorep |
| PMID 33426543 | Molecular Tools for Metastatic Colorectal Cancer Characterization. | Journal of cellular immunology | 2020 | name in abstract: pelareorep |
| PMID 30462296 | Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. | Japanese journal of clinical oncology | 2019 | name in abstract: pelareorep |
| PMID 30636617 | New Anti-Cancer Strategies in Testicular Germ Cell Tumors. | Recent patents on anti-cancer drug discovery | 2019 | name in abstract: pelareorep |
| PMID 31679206 | Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy. | Critical reviews in oncogenesis | 2019 | name in abstract: pelareorep |
| PMID 29799479 | A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. | Cancers | 2018 | name in title: pelareorep |
| PMID 30261620 | The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. | Cancers | 2018 | name in abstract: pelareorep |
| PMID 28812060 | Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. | Molecular therapy oncolytics | 2017 | name in title: Reolysin |
| PMID 29156834 | Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas. | Oncotarget | 2017 | name in abstract: pelareorep |
| PMID 26709987 | Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. | Cancer | 2016 | name in abstract: Reolysin |
| PMID 26809490 | Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. | Molecular cancer therapeutics | 2016 | name in abstract: Reolysin |
| PMID 27019795 | Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. | World journal of methodology | 2016 | name in abstract: Reolysin |
| PMID 27486853 | Oncolytic virus therapy: A new era of cancer treatment at dawn. | Cancer science | 2016 | name in abstract: pelareorep |
| PMID 25341011 | Recent therapeutic advances in the treatment of colorectal cancer. | Annual review of medicine | 2015 | name in abstract: Reolysin |
| PMID 25693885 | The oncolytic virus, pelareorep, as a novel anticancer agent: a review. | Investigational new drugs | 2015 | name in title: pelareorep |
| PMID 26513296 | Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. | Oncotarget | 2015 | name in abstract: Reolysin |
| PMID 30190838 | Oncolytics Biotech® Inc.: REOLYSIN® for melanoma therapy. | Melanoma management | 2015 | name in title: Reolysin |
| PMID 24419798 | Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production. | Applied microbiology and biotechnology | 2014 | name in title: pelareorep |
| PMID 23824333 | Live viruses to treat cancer. | Journal of the Royal Society of Medicine | 2013 | name in abstract: Reolysin |
| PMID 23868061 | Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. | Cell death & disease | 2013 | name in title: Reolysin |
| PMID 24121993 | Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats. | Investigational new drugs | 2013 | name in title: pelareorep |
| PMID 22002308 | Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. | Oncogene | 2012 | name in abstract: Reolysin |
| PMID 21472724 | Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. | Cancer | 2011 | name in title: Reolysin |
| PMID 20024838 | AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 1. | IDrugs : the investigational drugs journal | 2010 | name in abstract: Reolysin |
| PMID 20801221 | The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors. | Methods (San Diego, Calif.) | 2010 | name in abstract: Reolysin |
| PMID 19527106 | Reovirus-based therapy for cancer. | Expert opinion on biological therapy | 2009 | name in abstract: Reolysin |
| PMID 19806501 | Reovirus: Rationale and clinical trial update. | Current opinion in molecular therapeutics | 2009 | name in abstract: Reolysin |
| PMID 18632239 | Rapid and reliable quantification of reovirus type 3 by high performance liquid chromatography during manufacturing of Reolysin. | Journal of pharmaceutical and biomedical analysis | 2008 | name in title: Reolysin |
| PMID 18773127 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2008 | name in abstract: Reolysin |
| PMID 18806898 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2008 | name in abstract: Reolysin |
| PMID 19012507 | Reovirus therapy in cancer: has the orphan virus found a home? | Expert opinion on investigational drugs | 2008 | name in abstract: Reolysin |
| PMID 17440629 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2007 | name in abstract: Reolysin |
| PMID 18473990 | Molecular targeting in pancreatic cancer. | Reviews on recent clinical trials | 2007 | name in abstract: Reolysin |
| PMID 16774045 | Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic. | Current opinion in molecular therapeutics | 2006 | name in title: Reolysin |
| PMID 17167712 | Reovirus - possible therapy of cancer. | Neoplasma | 2006 | name in abstract: Reolysin |
| PMID 15676074 | Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus). | Health and quality of life outcomes | 2005 | name in title: Reolysin |
| PMID 14685303 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2003 | name in abstract: Reolysin |
| PMID 12113234 | Oncolytics Biotech releases REOLYSIN phase I clinical trial results. | Expert review of anticancer therapy | 2002 | name in title: Reolysin |
Unconfirmed matches (14)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 7745749 | Brain- and intestine-specific variants of reovirus serotype 3 strain dearing are selected during chronic infection of severe combined immunodeficient mice. | Journal of virology | 1995 | name in title: Reovirus Serotype 3 |
| PMID 8054525 | Reovirus serotype 3 infection in infants with extrahepatic biliary atresia or neonatal hepatitis. | Journal of gastroenterology and hepatology | 1994 | name in title: Reovirus Serotype 3 |
| PMID 8383165 | Tumor necrosis factor-alpha induction by reovirus serotype 3. | Journal of leukocyte biology | 1993 | name in title: Reovirus Serotype 3 |
| PMID 1870214 | The Lang strain of reovirus serotype 1 and the Dearing strain of reovirus serotype 3 differ in their sensitivities to beta interferon. | Journal of virology | 1991 | name in title: Reovirus Serotype 3 |
| PMID 2154608 | Passive immunity to fatal reovirus serotype 3-induced meningoencephalitis mediated by both secretory and transplacental factors in neonatal mice. | Journal of virology | 1990 | name in title: Reovirus Serotype 3 |
| PMID 2523177 | The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu 2 and the major nonstructural protein mu NS, respectively. | Virology | 1989 | name in title: Reovirus Serotype 3 |
| PMID 2549167 | Antibody inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the central nervous system. | The Journal of experimental medicine | 1989 | name in title: Reovirus Serotype 3 |
| PMID 2718385 | The sequences of the S2 genome segments of reovirus serotype 3 and of the dsRNA-negative mutant ts447. | Virology | 1989 | name in title: Reovirus Serotype 3 |
| PMID 3267236 | The sequence of the reovirus serotype 3 L3 genome segment which encodes the major core protein lambda 1. | Virology | 1988 | name in title: Reovirus Serotype 3 |
| PMID 3553613 | Evidence that the sigma 1 protein of reovirus serotype 3 is a multimer. | Journal of virology | 1987 | name in title: Reovirus Serotype 3 |
| PMID 3799063 | Expression of the cloned S4 gene of reovirus serotype 3 in transformed eucaryotic cells: enrichment of the viral protein in the crude initiation factor fraction. | Virus research | 1986 | name in title: Reovirus Serotype 3 |
| PMID 6095208 | Molecular cloning and sequencing of the reovirus (serotype 3) S1 gene which encodes the viral cell attachment protein sigma 1. | Nucleic acids research | 1984 | name in title: Reovirus Serotype 3 |
| PMID 6546631 | Molecular cloning of the complete genome of reovirus serotype 3. | Virology | 1984 | name in title: Reovirus Serotype 3 |
| PMID 6927854 | Sequence at both termini of the 10 genes of reovirus serotype 3 (strain Dearing). | Virology | 1982 | name in title: Reovirus Serotype 3 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R50CA252135 | Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic Interventions | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE | CASERTA, ENRICO | 2021–2025 | name in abstract: Reolysin |
| R01CA194742 | Reolysin-based combination therapy in relapsed multiple myeloma | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE | PICHIORRI, FLAVIA | 2016–2021 | name in title: Reolysin |
| F30CA210334 | Balancing Efficacy and Toxicity of Intratumoral Reolysin for Diffuse Intrinsic Pontine Glioma (DIPG) | MAYO CLINIC ROCHESTER | SCHUELKE, MATTHEW | 2016–2020 | name in title: Reolysin |
| R01CA190789 | Endoplasmic reticulum stress and oncoviral therapy | UNIVERSITY OF ARIZONA | NAWROCKI, STEFFAN T | 2015–2020 | name in abstract: Reolysin |
| P30CA013330 | Protocol - Specific Research Support | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC | GOLDMAN, ISRAEL DAVID | 2013–2017 | name in abstract: Reolysin |
Notes
Unmodified wild-type reovirus isolate; no transgenes.
How to cite
pelareorep (AXP000004.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000004.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.